# Smith & Wesson Brands, Inc.: financial statements, quarterly

SWBI · Nasdaq · CIK 1092796 · [Industrials](/sectors/industrials.md) · fiscal year ends Apr 30

Pages: [Overview](/companies/swbi.md) · [Financials](/companies/swbi/financials.md) · [Filings](/companies/swbi/filings.md) · [Insiders](/companies/swbi/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/swbi/financials.md?period=annual).

## Income statement

| Line item | Unit | Q2 FY2024 (2023-10-31) | Q3 FY2024 (2024-01-31) | Q4 FY2024 (2024-04-30) | Q1 FY2025 (2024-07-31) | Q2 FY2025 (2024-10-31) | Q3 FY2025 (2025-01-31) | Q4 FY2025 (2025-04-30) | Q1 FY2026 (2025-07-31) | Q2 FY2026 (2025-10-31) | Q3 FY2026 (2026-01-31) | Q4 FY2026 (2026-04-30) | Q1 FY2027 (2026-07-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [125](/filings/0000950170-24-133685.md) | [137](/filings/0000950170-25-034659.md) | [159 d](/filings/0001193125-26-274254.md) | [88.3](/filings/0000950170-25-113031.md) | [130](/filings/0001193125-25-308093.md) | [116](/filings/0001193125-26-093991.md) | [141 d](/filings/0001193125-26-274254.md) | [85.1](/filings/0001193125-26-381911.md) | [125](/filings/0001193125-25-308093.md) | [136](/filings/0001193125-26-093991.md) | [178 d](/filings/0001193125-26-274254.md) | [113](/filings/0001193125-26-381911.md) |
| Cost of revenue | $m | [93.2](/filings/0000950170-24-133685.md) | [98.1](/filings/0000950170-25-034659.md) | [103 d](/filings/0001193125-26-274254.md) | [64.1](/filings/0000950170-25-113031.md) | [95.2](/filings/0001193125-25-308093.md) | [87.9](/filings/0001193125-26-093991.md) | [100 d](/filings/0001193125-26-274254.md) | [63.0](/filings/0001193125-26-381911.md) | [94.3](/filings/0001193125-25-308093.md) | [100](/filings/0001193125-26-093991.md) | [125 d](/filings/0001193125-26-274254.md) | [80.3](/filings/0001193125-26-381911.md) |
| Gross profit | $m | [31.8](/filings/0000950170-24-133685.md) | [39.4](/filings/0000950170-25-034659.md) | [56.5 d](/filings/0001193125-26-274254.md) | [24.2](/filings/0000950170-25-113031.md) | [34.5](/filings/0001193125-25-308093.md) | [27.9](/filings/0001193125-26-093991.md) | [40.5 d](/filings/0001193125-26-274254.md) | [22.1](/filings/0001193125-26-381911.md) | [30.3](/filings/0001193125-25-308093.md) | [35.6](/filings/0001193125-26-093991.md) | [53.1 d](/filings/0001193125-26-274254.md) | [32.3](/filings/0001193125-26-381911.md) |
| Research and development | $m | [1.7](/filings/0000950170-24-133685.md) | [2.0](/filings/0000950170-25-034659.md) | [1.8 d](/filings/0001193125-26-274254.md) | [2.5](/filings/0000950170-25-113031.md) | [2.2](/filings/0001193125-25-308093.md) | [2.9](/filings/0001193125-26-093991.md) | [2.0 d](/filings/0001193125-26-274254.md) | [3.0](/filings/0001193125-26-381911.md) | [2.4](/filings/0001193125-25-308093.md) | [2.4](/filings/0001193125-26-093991.md) | [2.5 d](/filings/0001193125-26-274254.md) | [2.6](/filings/0001193125-26-381911.md) |
| Operating income | $m | [3.8](/filings/0000950170-24-133685.md) | [11.3](/filings/0000950170-25-034659.md) | [27.7 d](/filings/0001193125-26-274254.md) | [(1.5)](/filings/0000950170-25-113031.md) | [7.5](/filings/0001193125-25-308093.md) | [4.7](/filings/0001193125-26-093991.md) | [13.1 d](/filings/0001193125-26-274254.md) | [(3.0)](/filings/0001193125-26-381911.md) | [4.1](/filings/0001193125-25-308093.md) | [6.7](/filings/0001193125-26-093991.md) | [21.3 d](/filings/0001193125-26-274254.md) | [4.2](/filings/0001193125-26-381911.md) |
| Interest expense | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | [0.8](/filings/0000950170-24-133685.md) | [2.4](/filings/0000950170-25-034659.md) | [5.7 d](/filings/0001193125-26-274254.md) | [(0.4)](/filings/0000950170-25-113031.md) | [1.6](/filings/0001193125-25-308093.md) | [0.9](/filings/0001193125-26-093991.md) | [3.7 d](/filings/0001193125-26-274254.md) | [(0.7)](/filings/0001193125-26-381911.md) | [1.1](/filings/0001193125-25-308093.md) | [1.6](/filings/0001193125-26-093991.md) | [4.6 d](/filings/0001193125-26-274254.md) | [1.4](/filings/0001193125-26-381911.md) |
| Net income | $m | [2.5](/filings/0000950170-24-133685.md) | [7.9](/filings/0000950170-25-034659.md) | [27.9 d](/filings/0001193125-26-274254.md) | [(1.9)](/filings/0000950170-25-113031.md) | [4.5](/filings/0001193125-25-308093.md) | [2.1](/filings/0001193125-26-093991.md) | [8.6 d](/filings/0001193125-26-274254.md) | [(3.4)](/filings/0001193125-26-381911.md) | [1.9](/filings/0001193125-25-308093.md) | [3.8](/filings/0001193125-26-093991.md) | [16.2 d](/filings/0001193125-26-274254.md) | [2.6](/filings/0001193125-26-381911.md) |
| Diluted EPS | $ per share | [0.05](/filings/0000950170-24-133685.md) | [0.17](/filings/0000950170-25-034659.md) | not reported | [(0.04)](/filings/0000950170-25-113031.md) | [0.10](/filings/0001193125-25-308093.md) | [0.05](/filings/0001193125-26-093991.md) | not reported | [(0.08)](/filings/0001193125-26-381911.md) | [0.04](/filings/0001193125-25-308093.md) | [0.08](/filings/0001193125-26-093991.md) | not reported | [0.06](/filings/0001193125-26-381911.md) |
| Basic EPS | $ per share | [0.05](/filings/0000950170-24-133685.md) | [0.17](/filings/0000950170-25-034659.md) | not reported | [(0.04)](/filings/0000950170-25-113031.md) | [0.10](/filings/0001193125-25-308093.md) | [0.05](/filings/0001193125-26-093991.md) | not reported | [(0.08)](/filings/0001193125-26-381911.md) | [0.04](/filings/0001193125-25-308093.md) | [0.08](/filings/0001193125-26-093991.md) | not reported | [0.06](/filings/0001193125-26-381911.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: not reported
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q2 FY2024 (2023-10-31) | Q3 FY2024 (2024-01-31) | FY2024 (2024-04-30) | Q1 FY2025 (2024-07-31) | Q2 FY2025 (2024-10-31) | Q3 FY2025 (2025-01-31) | FY2025 (2025-04-30) | Q1 FY2026 (2025-07-31) | Q2 FY2026 (2025-10-31) | Q3 FY2026 (2026-01-31) | FY2026 (2026-04-30) | Q1 FY2027 (2026-07-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [44.2](/filings/0000950170-23-068840.md) | [47.4](/filings/0000950170-24-027968.md) | [60.8](/filings/0000950170-25-088157.md) | [35.5](/filings/0000950170-24-104004.md) | [39.1](/filings/0000950170-24-133685.md) | [26.7](/filings/0000950170-25-034659.md) | [25.2](/filings/0001193125-26-274254.md) | [18.0](/filings/0000950170-25-113031.md) | [22.4](/filings/0001193125-25-308093.md) | [18.4](/filings/0001193125-26-093991.md) | [28.2](/filings/0001193125-26-381911.md) | [18.7](/filings/0001193125-26-381911.md) |
| Current assets | $m | [282](/filings/0000950170-23-068840.md) | [276](/filings/0000950170-24-027968.md) | [287](/filings/0000950170-25-088157.md) | [285](/filings/0000950170-24-104004.md) | [306](/filings/0000950170-24-133685.md) | [299](/filings/0000950170-25-034659.md) | [277](/filings/0001193125-26-274254.md) | [276](/filings/0000950170-25-113031.md) | [269](/filings/0001193125-25-308093.md) | [262](/filings/0001193125-26-093991.md) | [241](/filings/0001193125-26-381911.md) | [247](/filings/0001193125-26-381911.md) |
| Total assets | $m | [573](/filings/0000950170-23-068840.md) | [571](/filings/0000950170-24-027968.md) | [577](/filings/0000950170-25-088157.md) | [571](/filings/0000950170-24-104004.md) | [587](/filings/0000950170-24-133685.md) | [579](/filings/0000950170-25-034659.md) | [560](/filings/0001193125-26-274254.md) | [555](/filings/0000950170-25-113031.md) | [549](/filings/0001193125-25-308093.md) | [538](/filings/0001193125-26-093991.md) | [513](/filings/0001193125-26-381911.md) | [523](/filings/0001193125-26-381911.md) |
| Current liabilities | $m | [90.9](/filings/0000950170-23-068840.md) | [86.1](/filings/0000950170-24-027968.md) | [94.4](/filings/0000950170-25-088157.md) | [80.5](/filings/0000950170-24-104004.md) | [77.2](/filings/0000950170-24-133685.md) | [64.0](/filings/0000950170-25-034659.md) | [66.6](/filings/0001193125-26-274254.md) | [52.9](/filings/0000950170-25-113031.md) | [53.9](/filings/0001193125-25-308093.md) | [58.1](/filings/0001193125-26-093991.md) | [75.4](/filings/0001193125-26-381911.md) | [68.4](/filings/0001193125-26-381911.md) |
| Total liabilities | $m | [199](/filings/0000950170-23-068840.md) | [194](/filings/0000950170-24-027968.md) | [178](/filings/0000950170-25-088157.md) | [193](/filings/0000950170-24-104004.md) | [218](/filings/0000950170-24-133685.md) | [215](/filings/0000950170-25-034659.md) | [187](/filings/0001193125-26-274254.md) | [190](/filings/0000950170-25-113031.md) | [185](/filings/0001193125-25-308093.md) | [175](/filings/0001193125-26-093991.md) | [136](/filings/0001193125-26-381911.md) | [150](/filings/0001193125-26-381911.md) |
| Shareholders' equity | $m | [374](/filings/0000950170-25-034659.md) | [376](/filings/0000950170-25-034659.md) | [400](/filings/0001193125-26-274254.md) | [380](/filings/0001193125-25-308093.md) | [371](/filings/0001193125-26-093991.md) | [367](/filings/0001193125-26-093991.md) | [372](/filings/0001193125-26-381911.md) | [364](/filings/0001193125-26-381911.md) | [363](/filings/0001193125-26-093991.md) | [363](/filings/0001193125-26-093991.md) | [377](/filings/0001193125-26-381911.md) | [374](/filings/0001193125-26-381911.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q2 FY2024 (2023-10-31) | Q3 FY2024 (2024-01-31) | Q4 FY2024 (2024-04-30) | Q1 FY2025 (2024-07-31) | Q2 FY2025 (2024-10-31) | Q3 FY2025 (2025-01-31) | Q4 FY2025 (2025-04-30) | Q1 FY2026 (2025-07-31) | Q2 FY2026 (2025-10-31) | Q3 FY2026 (2026-01-31) | Q4 FY2026 (2026-04-30) | Q1 FY2027 (2026-07-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(2.9) d](/filings/0000950170-24-133685.md) | [25.2 d](/filings/0000950170-25-034659.md) | [43.7 d](/filings/0001193125-26-274254.md) | [(30.8)](/filings/0000950170-25-113031.md) | [(7.4) d](/filings/0001193125-25-308093.md) | [(9.8) d](/filings/0001193125-26-093991.md) | [40.8 d](/filings/0001193125-26-274254.md) | [(8.1)](/filings/0001193125-26-381911.md) | [27.3 d](/filings/0001193125-25-308093.md) | [20.5 d](/filings/0001193125-26-093991.md) | [74.6 d](/filings/0001193125-26-274254.md) | [(8.8)](/filings/0001193125-26-381911.md) |
| Capital expenditure | $m | [34.9 d](/filings/0000950170-24-133685.md) | [18.2 d](/filings/0000950170-25-034659.md) | [5.6 d](/filings/0001193125-26-274254.md) | [4.7](/filings/0000950170-25-113031.md) | [3.3 d](/filings/0001193125-25-308093.md) | [6.3 d](/filings/0001193125-26-093991.md) | [7.3 d](/filings/0001193125-26-274254.md) | [4.3](/filings/0001193125-26-381911.md) | [11.0 d](/filings/0001193125-25-308093.md) | [3.6 d](/filings/0001193125-26-093991.md) | [4.8 d](/filings/0001193125-26-274254.md) | [11.9](/filings/0001193125-26-381911.md) |
| Dividends paid | $m | [5.5 d](/filings/0000950170-24-133685.md) | [5.5 d](/filings/0000950170-25-034659.md) | [5.5 d](/filings/0001193125-26-274254.md) | [5.9](/filings/0000950170-25-113031.md) | [5.8 d](/filings/0001193125-25-308093.md) | [5.7 d](/filings/0001193125-26-093991.md) | [5.7 d](/filings/0001193125-26-274254.md) | [5.9](/filings/0001193125-26-381911.md) | [5.8 d](/filings/0001193125-25-308093.md) | [5.8 d](/filings/0001193125-26-093991.md) | [5.8 d](/filings/0001193125-26-274254.md) | [6.0](/filings/0001193125-26-381911.md) |
| Share repurchases | $m | [8.2 d](/filings/0000950170-24-133685.md) | [0.9 d](/filings/0000950170-25-034659.md) | [1.1 d](/filings/0001193125-26-274254.md) | [12.9](/filings/0000950170-25-113031.md) | [9.8 d](/filings/0001193125-25-308093.md) | [2.8 d](/filings/0001193125-26-093991.md) | [0.0 d](/filings/0001193125-26-274254.md) | [0.0](/filings/0000950170-25-113031.md) | [0.0 d](/filings/0001193125-25-308093.md) | [0.0 d](/filings/0001193125-26-093991.md) | [0.0 d](/filings/0001193125-26-274254.md) | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Dividends paid: us-gaap:PaymentsOfDividends
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q2 FY2023 (2022-10-31) | Q3 FY2023 (2023-01-31) | Q1 FY2024 (2023-07-31) | Q2 FY2024 (2023-10-31) | Q3 FY2024 (2024-01-31) | Q1 FY2025 (2024-07-31) | Q2 FY2025 (2024-10-31) | Q3 FY2025 (2025-01-31) | Q1 FY2026 (2025-07-31) | Q2 FY2026 (2025-10-31) | Q3 FY2026 (2026-01-31) | Q1 FY2027 (2026-07-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [46.1](/filings/0000950170-23-068840.md) | [46.2](/filings/0000950170-24-027968.md) | [46.6](/filings/0000950170-24-104004.md) | [46.4](/filings/0000950170-24-133685.md) | [46.0](/filings/0000950170-25-034659.md) | [45.3](/filings/0000950170-25-113031.md) | [44.9](/filings/0001193125-25-308093.md) | [44.4](/filings/0001193125-26-093991.md) | [44.3](/filings/0001193125-26-381911.md) | [44.7](/filings/0001193125-25-308093.md) | [45.0](/filings/0001193125-26-093991.md) | [45.5](/filings/0001193125-26-381911.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 44,839,680 at 2026-09-01, from the cover of the [10-Q filed 2026-09-03](/filings/0001193125-26-381911.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:33 ET. No prices; not investment advice.